| Autor: |
Taffarel, Maiara, Silva, Bianca Sulzbacher da, Paulino, Angélica Macedo Borgês, Telles, Luciana Ortega, Mendonça, Sabrina Trigueiro, Santos, Cintia Vieira dos, Giordani, Morenna Alana, Nascimento, André Ferreira, Aguiar, Danilo Henrique, Sinhorin, Valéria Dornelles Gindri, Andrighetti, Carla Regina, Luvizotto, Renata de Azevedo Melo, Bomfim, Gisele Facholi |
| Předmět: |
|
| Zdroj: |
Biology (2079-7737); Nov2024, Vol. 13 Issue 11, p853, 10p |
| Abstrakt: |
Simple Summary: This study explores the potential benefits of copaiba oleoresin, a substance from a tree native to the Amazon, for treating liver cirrhosis, a severe and advanced liver condition with few treatment options. An animal model where cirrhosis was induced with a chemical called TAA was used. The animals were then given daily doses of copaiba oleoresin. The study found that the treatment helped the animals gain weight and body fat, which is often lost in cirrhosis, and reduced signs of inflammation. In particular, the liver showed higher levels of IL-10, a protein that helps reduce inflammation. Despite these benefits, copaiba oleoresin did not improve the overall liver damage markers, likely due to the severity of the disease. This suggests that while copaiba oleoresin may help manage some symptoms of cirrhosis, it may not fully reverse the condition at more advanced stages. Copaifera sp. is a native tree in the Amazon region. Copaiba oleoresin has components such as sesquiterpenes, which have anti-inflammatory and antioxidant potential. Liver cirrhosis is the end stage of liver disease with limited therapeutic options. We aimed to evaluate the effect of copaiba oleoresin supplementation on the liver of animals with thioacetamide (TAA)-induced cirrhosis. For the induction of liver cirrhosis, 100 mg/kg of TAA was administered intraperitoneally twice a week for 8 weeks. A total of 200 mg/kg/day of copaiba oleoresin was administered via gavage for the same period. Copaiba oleoresin supplementation improved cirrhosis-associated cachexia by increasing weight gain and body fat. In addition, copaiba oleoresin attenuated systemic inflammation, as shown by the decrease in the circulating C-reactive protein. In the liver, the copaiba oleoresin decreased carbonyl proteins and increased IL-10 compared with TAA-treated rats. TAA groups demonstrated increased SOD, catalase, GST, and GSH activity in the liver. In conclusion, the supplementation of copaiba oleoresin demonstrated a beneficial systemic effect in alleviating cirrhotic cachexia and antioxidant and anti-inflammatory action in the liver. However, it failed to improve the serological and histological markers of liver damage, which could be associated with the advanced stage of the disease. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
